The document builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies.
FDA announced the availability of the draft guidance, E6(R3) Good Clinical Practice (GCP) on June 5, 2023. Prepared by the International Council for Harmonisation (ICH), the GCP guideline provides a standard for facilitating a mutual acceptance of clinical trial data for ICH member countries and regions by applicable regulatory authorities. According to the guidance, the document builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies.
This includes, but is not limited to, fostering a quality culture and designing quality into clinical trials and drug development planning, identifying factors critical to trial quality, and engaging stakeholders. Further, this guideline is applicable to other interventional clinical trials of investigational products that are not intended to support marketing authorization applications in accordance with local requirements.
The principles outlined in the guidance are intended to apply across clinical trial types and settings and to remain relevant as technological and methodological advances happen, according to the guidance. It should also be read in conjunction with other ICH guidelines relevant to the design and conduct of clinical trials.
Source: FDA
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.